<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568578</url>
  </required_header>
  <id_info>
    <org_study_id>2017ZX10203202002</org_study_id>
    <nct_id>NCT03568578</nct_id>
  </id_info>
  <brief_title>A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers</brief_title>
  <official_title>A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to validate the non-invasive model which was constructed by our
      previous study for evaluating liver fibrosis or cirrhosis caused by hepatitis B virus in
      mainland China and to find a therapeutic regimen to reverse liver fibrosis and cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      450 patients who are infected with hepatitis B virus for at least 6 months will be included
      in the study. They will be divided into two groups. One group will be treated with Entecavir
      while another treated with Entecavir and Anluohuaxian Pill. Liver biopsy samples and blood
      samples from the patients will be used to validate the non-invasive model. Furthermore, the
      samples will be used to evaluate if Anluohuaxian Pill could reverse liver fibrosis and
      cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Construct a non-invasive model based on laboratory tests</measure>
    <time_frame>26 weeks after liver biopsy</time_frame>
    <description>We will measure the following biomarkers: TIMP1，CXCL10，CD25，YKL-40，collagen IV，von Willebrand Factor，TGF-β1，ANGPTL2，MMP-9，IL-2R，PDGF-AA，PDGF-BB，TGF-a，LN，MMP-1, soluble CD163 and CXCL9. To formulate the predictive models for detecting significant fibrosis (Ishak fibrosis score ≥3)， univariate analysis was performed on variables between patients with and without significant fibrosis. The significant variables (p＜0.05) were then subjected to multivariate stepwise logistic regression, using backward approaches, and were combined using the logistic regression function. The diagnostic value of each regression model was assessed using receiver operating characteristics curves.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the difference of fibrosis reverse rates between the two groups</measure>
    <time_frame>26 weeks after liver biopsy</time_frame>
    <description>Liver biopsy samples will be evaluated by Ishak fibrosis score. Then we compare the difference of fibrosis reverse rates between the two groups by Ishak fibrosis score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Entecavir Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will be given Entecavir 0.5 mg a day for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir and Anluohuaxian Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will be given Entecavir 0.5 mg and Anluohuaxian Pill 12 g a day for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir 0.5 mg</intervention_name>
    <description>Patients in this group will be given Entecavir 0.5 mg a day for 2 years.</description>
    <arm_group_label>Entecavir Group</arm_group_label>
    <arm_group_label>Entecavir and Anluohuaxian Group</arm_group_label>
    <other_name>ETV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anluohuaxian Pill 12g</intervention_name>
    <description>Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years</description>
    <arm_group_label>Entecavir and Anluohuaxian Group</arm_group_label>
    <other_name>ALHX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HBsAg positive for at least 6 months

          2. Agree to have liver biopsy

          3. Male or female aged 18 to 70 years old -

        Exclusion Criteria:

          1. Patients with alcoholic liver disease, autoimmune liver disease, heretic liver
             disease, drug induced liver disease, nonalcoholic liver disease or other chronic liver
             disease

          2. Platelet count &lt; 80 × 10^9/L

          3. Prothrombin activity ≤ 60%

          4. Decompensated liver cirrhosis

          5. Patients with any disease or condition which the investigator or treating physician
             feels would interfere with the trial or the safety of the subject -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guiqiang Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guiqiang Wang</last_name>
    <phone>13911405123</phone>
    <email>john131212@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Zhao</last_name>
    <phone>13810765943</phone>
    <email>minmin2001@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guiqiang Wang</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiqiang Wang</last_name>
      <phone>13911405123</phone>
      <email>john131212@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Zhao</last_name>
      <phone>86-13810765942</phone>
      <email>minmin2001@gmail.comc</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinghua Meng</last_name>
      <phone>13601398756</phone>
      <email>wj5773@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fudong Lv</last_name>
      <phone>13681547749</phone>
      <email>lfd@tom.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haibin Yu</last_name>
      <phone>13811669802</phone>
      <email>xiaobenyu2002@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anlin Ma</last_name>
      <phone>13910253710</phone>
      <email>maanlinjc@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Wang</last_name>
      <phone>13601004423</phone>
      <email>wangyanwang@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongsong Chen</last_name>
      <phone>13501196710</phone>
      <email>chenhongsong@pkuph.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dazhi Zhang</last_name>
      <phone>86-13452382818</phone>
      <email>zhangdzh@etang.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Fan</last_name>
      <phone>13143522264</phone>
      <email>rongfansmu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo Zhang</last_name>
      <phone>13978839646</phone>
      <email>zhangguogx@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Kang</last_name>
      <phone>13938553839</phone>
      <email>13938553839@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Li</last_name>
      <phone>13905175333</phone>
      <email>dr-lijun@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi the Fifth People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Huang</last_name>
      <phone>13601513551</phone>
      <email>huanglihua@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanqing Zhang</last_name>
      <phone>18916039958</phone>
      <email>doctorzzqsphc@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Honglian Gui</last_name>
      <phone>13564725017</phone>
      <email>lillian_ghl@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lang Bai</last_name>
      <phone>18980602254</phone>
      <email>pangbailang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang First Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weifeng Liang</last_name>
      <phone>13957163061</phone>
      <email>dr.liangwf@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Guiqiang Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fibrosis</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>non-invasive biopsy</keyword>
  <keyword>hepatitis B virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

